Artigo Tablet

Brand Name: Artigo
Generic: Cinnarizine + Dimenhydrinate
Weight: 20 mg+40 mg
Type: Tablet
Therapeutic Class: Anti vertigo drugs
Manufacturer: ACI Limited.
Price: 2.80
Last Updated: 2020-11-21 18:15:00

Artigo Tablet Uses

Artigo Tablet contains Cinnarizine + Dimenhydrinate. Artigo uses:

Cinnarizine + Dimenhydrinate is indicated for the treatment of vertigo symptoms of various origins.

Cerebral circulatory disorders: Prophylaxis and maintenance therapy for symptoms of cerebral vascular spasms and arteriosclerosis, Sequelae of cerebral and cranial trauma, Postapoplectic disorders, Migraine.

Peripheral circulatory disorders: Prophylaxis and maintenance therapy for symptoms of vascular spasms and arteriosclerosis (obliterating arteritis, thromboangitis obliterans, Raynaud's disease, diabetes, acrocyanosis pernio, etc.) such as intermittent claudication,trophic disturbances, pregangrene, trophic and varicose ulcers, paraesthesia, nocturnal cramps,cold extremities.

Disorders of balance: Prophylaxis and maintenance therapy for symptoms of labyrinthine arteriosclerosis; vestibular irritability;Meniere's syndrome such as vertigo, dizziness, giddiness, syncopal attacks, tinnitus, nystagmus, nausea and vomiting. Prophylaxis of motion sickness.

Artigo Tablet Doses

Artigo Tablet contains Cinnarizine + Dimenhydrinate 20 mg+40 mg. Artigo doses:

Adults: 1 tablet three times daily, to be taken unchewed with some liquid after meals.

Children and adolescents under the age of 18 years: Cinnarizine + Dimenhydrinate is not recommended in children and adolescents under the age of 18 years because there are no data available on the use of Cinnarizine + Dimenhydrinate in this age group.

Elderly: Dosage as for adults.

In general, the duration of treatment should not exceed four weeks. The physician shall decide whether longer treatment is required.

 

Side Effects

The most frequently occurring side-effects are somnolence and dry mouth. These reactions are usually mild and disappear within a few days even if treatment is continued. In addition the following adverse reactions are associated with dimenhydrinate and cinnarizine:

Dimenhydrinate: paradoxical excitability (especially in children), worsening of an existing angleclosure glaucoma and reversible agranulocytosis.

Cinnarizine: constipation, weight gain, tightness of the chest, cholestatic jaundice, extrapyramidal symptoms, lupus-like skin reactions, lichen planus.

Introduction

Cinnarizine + Dimenhydrinate consists of two compounds: cinnarizine and dimenhydrinate. Dimenhydrinate, the chlorotheophylline salt of diphenhydramine, acts as antihistamine with anticholinergic properties. The substance exhibits anti-emetic and antivertiginous effects through influencing the chemoreceptor trigger zone in the region of the 4th ventricle. Cinnarizine acts mainly as a vestibular sedative through inhibition of the calcium influx into the vestibular sensory cells. Cinnarizine thus acts predominantly on the peripheral vestibular system. The combination product is more effective than the individual compounds.

Artigo Precaution

 

Interaction

The anticholinergic and sedative effects of Cinnarizine & Dimenhydrinate may be potentiated by monoamine oxidase inhibitors. In common with other antihistamines, Cinnarizine & Dimenhydrinate may potentiate the sedative effects of CNS depressants including alcohol, barbiturates, narcotic analgesics and tranquillisers. Cinnarizine & Dimenhydrinate may also enhance the effects of antihypertensives, ephedrine and anticholinergics such as atropine and tricyclic antidepressants.

Pregnancy Lactation use

Pregnancy: The safety of Cinnarizine + Dimenhydrinate in human pregnancy has not been established.

Lactation: Dimenhydrinate and cinnarizine are excreted in human breast milk. Cinnarizine + Dimenhydrinate should not be taken by women who are breast feeding.

Contraindication

Contraindications are not known. Side-effects such as somnolence and gastrointestinal disturbances are extremely rare. They are transient and may be readily prevented by achieving the optimal dosage gradually. Combination therapy with other drugs is possible whenever indicated.

Special Warning

Children and adolescents under the age of 18 years: Revert is not recommended in children and adolescents under the age of 18 years because there are no data available on the use of Revert in this age group.

Elderly: Dosage as for adults. In general, the duration of treatment should not exceed four weeks. The physician shall decide whether longer treatment is required.

Acute Overdose

Symptoms of overdosage with Cinnarizine + Dimenhydrinate include drowsiness, dizziness and ataxia with anticholinergic effects such as dry mouth, flushing of the face, dilated pupils, tachycardia, pyrexia, headache and urinary retention. General supportive measures should be used to treat respiratory insufficiency or circulatory failure. Gastric lavage with isotonic sodium chloride solution is recommended. Cramp-like symptoms may be controlled by careful application of a short-acting barbiturate. In cases of marked central-anticholinergic effects, physostigmine (after physostigmine test) should be administered slowly intravenously (or, if necessary, intramuscularly): 0.03 mg/kg body weight (adults max. 2 mg, children max. 0.5 mg). Sufficient elimination can be achieved by means of haemoperfusion using activated charcoal.

Interaction with other Medicine

The anticholinergic and sedative effects of Cinnarizine + Dimenhydrinate may be potentiated by monoamine oxidase inhibitors. In common with other antihistamines, Cinnarizine + Dimenhydrinate may potentiate the sedative effects of CNS depressants including alcohol, barbiturates, narcotic analgesics and tranquillisers. Cinnarizine + Dimenhydrinate may also enhance the effects of antihypertensives, ephedrine and anticholinergics such as atropine and tricyclic antidepressants.

Storage Condition

Store below 30° C, away from light & moisture

Artigo Tablet price in Bangladesh 2.80